Group 1 - The company announced on August 8 that it received a written resignation report from its board secretary and director, Zhu Ting, who is resigning for personal reasons [1] - Zhu Ting's resignation as board secretary is effective immediately upon delivery of the resignation report to the board [1] - After resigning from the board secretary position, Zhu Ting will continue to serve as a director of the company [1] Group 2 - To ensure the normal operation of information disclosure and other duties, the company's chairman, Liu Yang, will temporarily act as the board secretary until a new board secretary is appointed [1]

证券代码：300878 证券简称：维康药业 公告编号：2025-030 朱婷女士辞任董事会秘书职务不会影响公司正常运作，公司将按照《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关法律法规、规范性文件及《公司章程》的 规定，尽快确定董事会秘书候选人并完成董事会秘书的聘任工作。 为保证公司信息披露等工作正常进行，在新任董事会秘书到任前，暂由公司 董事长刘洋先生代行董事会秘书职责。 公司董事长刘洋先生代行董事会秘书职责期间的联系方式如下： 电话：0578-2950005 浙江维康药业股份有限公司 关于公司董事会秘书辞职暨董事长代行董事会 秘书职责的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关于董事会秘书辞职的情况 浙江维康药业股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 8 日收到公司董事会秘书、董事朱婷女士提交的书面辞职报告。朱婷女士因个人原 因，申请辞去公司董事会秘书职务。根据《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》和《公 ...

Core Viewpoint - The article highlights serious financial misconduct at Weikang Pharmaceutical, including the misuse of company funds by its actual controller, Liu Zhongliang, and the subsequent impact on the company's financial performance and project timelines [3][4][6]. Financial Misconduct - Liu Zhongliang has occupied company funds totaling 157 million yuan, including 54 million yuan of raised funds, under the guise of paying for engineering equipment [1][4]. - The funds were ultimately transferred to personal accounts controlled by Liu Zhongliang, constituting non-operational fund occupation [3][4]. - The balances of fund occupation by the actual controller from 2020 to mid-2023 were 78.12 million yuan, 89.51 million yuan, 147.28 million yuan, and 151.22 million yuan, representing 5.64%, 6.35%, 10.43%, and 10.24% of net assets respectively [3][4]. Regulatory Actions - The Zhejiang Securities Regulatory Bureau has ordered Weikang Pharmaceutical to rectify the situation, issuing a warning and imposing a fine of 5 million yuan on the company and 7 million yuan on Liu Zhongliang [4][6]. Project Delays - Weikang Pharmaceutical's initial fundraising projects have faced multiple delays, with the first phase of the health industry park originally scheduled for completion in December 2020, now pushed back multiple times to 2025 [6][7]. - The marketing center project has also seen significant delays, with no new investments reported for 2023 and 2024 [7][8]. Financial Performance - The company's financial performance has deteriorated significantly since its IPO, with net profit dropping from 96 million yuan in 2021 to a loss of 147 million yuan in 2024 [9][10]. - Revenue has also declined from 633 million yuan in 2021 to 351 million yuan in 2024, contrasting sharply with pre-IPO growth [9][10]. Dividend Payments - Despite the losses, Weikang Pharmaceutical has continued to distribute dividends, with cash dividends of 35.51 million yuan in 2023 and 19.89 million yuan in 2024, even as the actual controller holds nearly 70% of the company's shares [11].

Market Performance - The Traditional Chinese Medicine (TCM) sector rose by 0.42% on August 4, with Longshen Rongfa leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in TCM Sector - Longshen Rongfa (300534) closed at 12.09, up 7.18% with a trading volume of 646,800 shares and a turnover of 777 million yuan [1] - Weikang Pharmaceutical (300878) closed at 27.26, up 6.40% with a trading volume of 198,700 shares and a turnover of 513 million yuan [1] - Darentang (600329) closed at 41.20, up 6.30% with a trading volume of 164,600 shares and a turnover of 664 million yuan [1] Top Losers in TCM Sector - Biotech Valley (833266) closed at 12.80, down 8.51% with a trading volume of 215,700 shares and a turnover of 271 million yuan [2] - Datang Pharmaceutical (836433) closed at 8.19, down 4.88% with a trading volume of 204,800 shares and a turnover of 166 million yuan [2] - Huason Pharmaceutical (002907) closed at 20.00, down 3.57% with a trading volume of 390,300 shares and a turnover of 787 million yuan [2] Capital Flow Analysis - The TCM sector experienced a net outflow of 556 million yuan from institutional investors, while retail investors saw a net inflow of 375 million yuan [2] - The net inflow from speculative funds was 181 million yuan [2] Individual Stock Capital Flow - China Resources Sanjiu (000999) had a net inflow of 86.17 million yuan from institutional investors, while retail investors saw a net outflow of 56.84 million yuan [3] - Yabao Pharmaceutical (600351) had a net inflow of 57.28 million yuan from institutional investors, with retail investors experiencing a net outflow of 42.13 million yuan [3] - Tongrentang (600085) had a net inflow of 53.69 million yuan from institutional investors, while retail investors had a net outflow of 58.73 million yuan [3]

A股中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]

Market Overview - On the first trading day of August, the A-share market experienced overall weakness, with major sectors such as oil and petrochemicals, semiconductors, and non-bank financials adjusting, leading to declines in the three major stock indices [2] - The Shanghai Composite Index closed at 3559.95 points, down 0.37%; the Shenzhen Component Index closed at 10991.32 points, down 0.17%; and the ChiNext Index closed at 2322.63 points, down 0.24% [2] - The total trading volume in the Shanghai and Shenzhen markets was 15,983 billion yuan, a decrease of over 3,300 billion yuan compared to the previous trading day [2] Solar Equipment Sector - The solar equipment sector showed strong performance, with the Shenwan Solar Equipment Index closing up 2.60%, leading all secondary industries [3] - Companies such as Jiejia Weichuang and Shuangliang Energy reached the daily limit [3] - The Ministry of Industry and Information Technology recently issued a special energy-saving inspection task list for the polysilicon industry for 2025, requiring local authorities to implement and report results by September 30 [3] - According to China International Capital Corporation (CICC), this move is aimed at optimizing the supply side of the industry and may lead to the exit of backward production capacity, particularly affecting the upstream polysilicon segment [3] Express Delivery Sector - The express delivery sector also performed actively, with the Shenwan Logistics Index rising by 1.53% [3] - Companies such as YTO Express, Shentong Express, and Yunda Holdings saw increases of over 6%, while other stocks like Debang Logistics also followed suit [3] - On July 29, the State Post Bureau held a meeting with express delivery companies to address issues related to "involution" competition and promote high-quality industry development [4] Innovative Drug Sector - The innovative drug sector remained active, with stocks like Weikang Pharmaceutical hitting a 20% daily limit, and companies such as Anglikang and Guizhou Bailin recording consecutive gains [5] - Recent announcements from companies like Haizike and Huahai Pharmaceutical regarding new drug applications have contributed to the sector's momentum [5] - According to Dongfang Securities, the global innovative drug field is shifting from "Made in China" to "Created in China," with domestic pharmaceutical companies enhancing their international competitiveness [5] Dividend and Resource Sectors - Looking ahead to August, the strategy team at Industrial Securities suggests focusing on dividend sectors and resource industries for investment opportunities [6] - Historical data indicates that the first half of August typically sees fewer companies disclosing semi-annual results, leading to a higher success rate for small-cap stocks [6] - As the month progresses and companies begin to report earnings, larger-cap stocks with earnings certainty are expected to gain more attention, particularly in resource sectors like coal and petrochemicals [6]

Core Viewpoint - On the first trading day of August, China's A-shares experienced a correction with major indices declining, but the traditional Chinese medicine sector showed resilience, rising significantly [1] Market Performance - The traditional Chinese medicine sector increased by 3.39%, leading all industry sectors in A-shares [1] - Notable individual stocks included Weikang Pharmaceutical, Tianmu Pharmaceutical, Xintian Pharmaceutical, and Huason Pharmaceutical, with Weikang Pharmaceutical achieving approximately a 20% increase [1] - The Shanghai Composite Index closed at 3559 points, down 0.37%; the Shenzhen Component Index closed at 10991 points, down 0.17%; and the ChiNext Index closed at 2322 points, down 0.24% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 15,984 billion RMB, a decrease of about 3,377 billion RMB compared to the previous trading day [1] Industry Developments - The Long Triangle Traditional Chinese Medicine Concept Verification and Achievement Transformation Center was officially launched, aiming to address early bottlenecks in the transformation of traditional Chinese medicine achievements [1] Analyst Insights - According to Guo Yiming, Director of Investment Advisory at Jifeng Investment Consulting, the decline in A-shares on August 1 was primarily a technical adjustment due to the indices reaching a phase high, coupled with profit-taking [1] - The overall outlook remains positive, with the fundamental recovery of the Chinese economy, improved market liquidity, and supportive policies indicating limited downward space for the indices in the future [1]

Market Performance - As of August 1, the pharmaceutical e-commerce sector rose by 1.51%, ranking 9th among concept sectors, with 114 stocks increasing in value [1] - Notable gainers included Weikang Pharmaceutical with a 20% limit-up, and New Tian Pharmaceutical, Huason Pharmaceutical, and Qizheng Tibetan Medicine also hitting the limit-up [1] - The top performers in the sector were Shenzhou Pharmaceutical, Dajia Weikang, and Zhongsheng Pharmaceutical, with increases of 23.15%, 8.87%, and 7.49% respectively [1] Capital Flow - The pharmaceutical e-commerce sector saw a net inflow of 899 million yuan from main funds, with 84 stocks receiving net inflows [2] - Leading the net inflow was Zhongsheng Pharmaceutical with 533 million yuan, followed by Huason Pharmaceutical, Taiji Group, and New Tian Pharmaceutical with net inflows of 111 million yuan, 98 million yuan, and 82 million yuan respectively [2] Stock Performance - New Tian Pharmaceutical, Weikang Pharmaceutical, and Kefu Medical had the highest net inflow ratios at 43.47%, 16.51%, and 15.73% respectively [3] - The top stocks in the pharmaceutical e-commerce sector based on net inflow included Zhongsheng Pharmaceutical, Huason Pharmaceutical, and Taiji Group, with respective daily increases of 7.49%, 10.03%, and 4.09% [3] Decliners - The stocks with the largest declines included Erkang Pharmaceutical, Kangzhi Pharmaceutical, and Laimei Pharmaceutical, which fell by 9.59%, 7.15%, and 5.81% respectively [1][10] - The overall market showed mixed performance with some sectors experiencing significant losses while others gained traction [10]

市场全天震荡调整，三大指数小幅收跌。 盘面上，医药板块全线逆势走强，创新药概念延续强势，昂利康（002940）涨停；中药股展开补涨，维 康药业（300878）涨停；光伏概念反弹，捷佳伟创（300724）涨停；午后AI应用端活跃，智能体方向 领涨，鼎捷数智（300378）涨超10%；数据要素概念走强，深桑达A涨停。下跌方面，体育概念集体调 整，共创草坪（605099）跌停。 截至收盘，沪指跌0.37%，深成指跌0.17%，创业板指跌0.24%。市场热点快速轮动，个股涨多跌少，全 市场超3300家个股上涨。沪深两市全天成交额1.60万亿，较上个交易日缩量3377亿。 市场再现"技术性调整" 今日，A股市场震荡调整，三大指数均小幅下跌，量能较昨日大幅萎缩。 对于最近两日A股的杀跌，机构认为主要还是技术性调整。一方面，从市场结构而言存在涨幅快速积累 后的回调需求，指数摸高至3600点的过程中，不少板块站上阶段性高位，资金获利离场。另一方面，中 报季来临，进入8月中报期，市场将要开始验证上市公司业绩成色。 消息面上，快递行业近期催化颇多。一是国家邮政局召开快递企业座谈会，就依法依规治理行业"内卷 式"竞争，强化农村地区 ...